Smith JR, et al. (2015) Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene 34, 15-26 24292678

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S473-p - Akt1 (human) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) no change compared to control

S13-p - CDC37 (human) ▲
Modsite: VWDHIEVsDDEDETH SwissProt Entrez-Gene Orthologous residues CDC37 (human): S13‑p, CDC37 (mouse): S13‑p, CDC37 (rat): S13‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) no change compared to control

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) no change compared to control

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) no change compared to control

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) no change compared to control

S780-p - Rb (human) ▲

Modsite: strPPtLsPIPHIPr SwissProt Entrez-Gene Orthologous residues Rb (human): S780‑p, Rb (mouse): S773‑p, Rb (rat): S772‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) increase CDC37 promotes stabiltity of CDK4 and does not affect its activity.

S795-p - Rb (human) ▲

Modsite: sPykFPssPLrIPGG SwissProt Entrez-Gene Orthologous residues Rb (human): S795‑p, Rb (mouse): S788‑p, Rb (rat): S787‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes CDC37 (human) increase CDC37 promotes stabiltity of CDK4 and does not affect its activity.